During the past decade, Stanford University - DCT Dept. conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Stanford University - DCT Dept." are "Advanced Solid Tumors" (1 trials), "Atrial Fibrillation" (1 trials) and "Prevention of Stroke or Systemic Embolism" (1 trials). Many other conditions were trialed in "Stanford University - DCT Dept." in a lesser frequency.

Most popular intervention types in "Stanford University - DCT Dept." are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Apixaban" (1 trials), "Apixaban matching placebo" (1 trials), "Asundexian (BAY2433334)" (1 trials), "Asundexian matching placebo" (1 trials) and "Elimusertib (BAY1895344)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Stanford University - DCT Dept." are 2 trials for "All" genders.

Currently, there are NaN active trials in "Stanford University - DCT Dept.". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Stanford University - DCT Dept., undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Stanford University - DCT Dept., 1 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".